Intranasal Oxytocin Trial Investigates Safety and Symptom Reduction in Childhood-Onset Schizophrenia

Childhood-onset schizophrenia is a severe neurodevelopmental disorder characterized by profound social and emotional deficits, hallucinations, and delusions. Current antipsychotic medications often fall short in fully addressing these complex symptoms, particularly the social and negative symptoms, leaving a significant treatment gap. Oxytocin, a neuropeptide known for its role in social bonding and emotional regulation, has shown promise in adult schizophrenia studies by potentially modulating social cognition and reducing symptom severity. However, its safety and efficacy in pediatric populations with childhood-onset schizophrenia remain largely unexplored, necessitating dedicated research into this vulnerable group.

This 4-week inpatient Phase 1 study enrolled 68 children over 10 years old with childhood-onset schizophrenia who remained symptomatic despite medication. After a 1-week screening period involving physical exams, medical/psychiatric history, blood and urine samples, and brain imaging, participants received either oxytocin nasal spray or placebo twice daily for 2 weeks. The oxytocin dose was not specified in the abstract but was administered intranasally. This was followed by a 1-week washout period, after which all initial tests were repeated. An optional 3-week extension included 2 weeks of open-label oxytocin and 1 week of further testing, with the primary endpoint being safety and symptom reduction.

This Phase 1 study is a protocol designed to investigate the safety and preliminary efficacy of intranasal oxytocin in children with childhood-onset schizophrenia. The primary objective is to assess the tolerability and safety profile of oxytocin administered twice daily over a 2-week period, with participants closely monitored in an inpatient setting. Researchers will meticulously track adverse events, vital signs, and laboratory parameters (blood, urine) to establish the drug's safety in this vulnerable population. Secondary objectives focus on evaluating potential changes in schizophrenia symptom severity, utilizing established psychiatric rating scales to quantify improvements in symptoms such as hallucinations, delusions, and social withdrawal.

The study aims to determine if daily intranasal oxytocin can reduce schizophrenia symptoms in children who remain symptomatic despite standard medication. Furthermore, assessments of social and emotional functioning will be conducted, alongside brain imaging studies (MRI) to explore potential neurobiological correlates of treatment response. The collection of biological samples will also facilitate the search for biomarkers that could predict treatment efficacy or shed light on the underlying mechanisms of oxytocin's action in schizophrenia. This foundational data will inform the design of subsequent larger-scale clinical trials.